NOT MEDICAL ADVICE

Retatrutide

Estimated Market Price
$149.99 $164.99
Based on verified supplier pricing for research-grade compounds
Triple-receptor agonist (GLP-1/GIP/Glucagon) — the most advanced weight management peptide available. Next-gen metabolic optimization.
How it works

Hits three hormone receptors at once (GLP-1, GIP, and glucagon) to suppress appetite, improve insulin response, and ramp up your body's fat-burning and energy expenditure.

Performance

Weight Management

trending new

What to Expect
Week 1–4 Triple-receptor activation initiating; appetite drops noticeably. Appetite drops fast; might feel nauseous the first week.
Week 5–8 Enhanced fat oxidation from glucagon arm; 5–8% weight loss. Weight melting off noticeably; energy surprisingly high.
Week 9–12 Full triple-agonist synergy; accelerated body recomposition. Dramatic body change; clothes don't fit anymore (in a good way).
Week 13–16 Peak weight-loss velocity; energy expenditure significantly elevated. People asking what you're doing; feeling leaner and lighter.
Week 17+ Maintenance phase; among the most potent weight-loss agents studied. Sustained results; appetite control feels effortless.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 0.5 mg/week titrating to 8–12 mg/week SC
Administration Subcutaneous injection
Schedule Once weekly, same day each week
Protocol Duration 12–16+ weeks
Half-Life ~6 days
Side Effects & Safety
Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

  • Nausea~35%
  • Diarrhea~25%
  • Decreased appetite~22%
  • Vomiting~20%
  • Constipation~10%
  • Abdominal pain~7%
  • Dyspepsia~6%

Less Common

  • Increased heart rate~4%
  • Gallbladder issues~2%
  • Eructation (burping)occasional
  • Flatulenceoccasional
  • Injection site reactionoccasional

Rare / Serious

  • Pancreatitis<0.5%
  • Hypoglycemia (with insulin)rare

Discontinue If

  • Severe abdominal pain radiating to back (pancreatitis)
  • Heart palpitations or chest pain
  • Neck lump, hoarseness, or swallowing difficulty (thyroid)
  • Persistent vomiting or dehydration

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • History of pancreatitis
  • Pregnancy or breastfeeding

Data note: Phase III trial data. Triple-agonist produces highest GI side effect rates among incretin therapies, particularly during titration.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about Retatrutide
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for Retatrutide

Also Known As LY3437943, Reta
Classification GLP-1/GIP/Glucagon Receptor Agonist · Metabolic
Sequence Triple incretin agonist (39 aa)
Molecular Formula C₂₁₄H₃₃₆N₄₈O₆₆
Molecular Weight ~4,483.91 Da
CAS Number 2381089-83-2
Half-Life ~6 days
Origin Synthetic triple incretin receptor agonist
Administration Subcutaneous injection
Status Phase III clinical trials (2024–2025)
Mechanism of Action Hits three hormone receptors at once (GLP-1, GIP, and glucagon) to suppress appetite, improve insulin response, and ramp up your body's fat-burning and energy expenditure.
Research Overview Retatrutide, designated LY3437943 by its developer Eli Lilly and Company, represents the next evolutionary step in incretin-based pharmacotherapy as the first triple-hormone receptor agonist to reach advanced clinical trials. While tirzepatide demonstrated the power of dual GIP/GLP-1 agonism, retatrutide adds a third target - the glucagon receptor - creating a triagonist that simultaneously activates GIP, GLP-1, and glucagon receptor pathways. The compound is a 39-amino-acid peptide with modifications providing a half-life suitable for once-weekly subcutaneous dosing. The rationale for glucagon receptor inclusion is pharmacologically compelling - while GLP-1 agonism reduces appetite and improves glycemic control, and GIP agonism enhances insulin sensitivity and lipid metabolism, glucagon receptor activation adds a fundamentally different dimension by increasing hepatic glucose production (counterbalanced by the GLP-1/GIP insulin effects), stimulating hepatic lipid oxidation and thermogenesis, and increasing energy expenditure. In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants receiving the highest dose of retatrutide achieved a mean body weight reduction of 24.2% at 48 weeks - the largest weight loss ever reported for any anti-obesity drug in clinical trials and approaching the results typically seen with Roux-en-Y gastric bypass surgery. Additionally, a sub-study evaluating hepatic steatosis (fatty liver) demonstrated that 90% of participants with metabolic dysfunction-associated steatotic liver disease achieved complete resolution of liver fat at 48 weeks, suggesting transformative potential for the global NASH/MASLD epidemic. Retatrutide is currently being evaluated in multiple Phase 3 clinical trials (the TRIUMPH program) with anticipated completion dates in 2025-2026, and if approved, would likely become the most efficacious pharmacological weight loss intervention available.

Citations

Published findings on Retatrutide from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.